Full-Spectrum Cannabis Extract Outperformed CBD Alone in Reducing Brain Cell Inflammation
A full-spectrum low-THC cannabis extract (NTI-164) significantly reduced microglial inflammation markers and protected neurons from excitotoxic damage in cell models, while CBD alone did not achieve the same anti-inflammatory effects.
Quick Facts
What This Study Found
NTI-164, a high-CBD/low-THC full-spectrum extract, significantly attenuated inflammation-induced upregulation of microglial inflammatory markers in BV-2 microglia, while CBD alone did not. NTI-164 also promoted neuron proliferation and survival under excitotoxic conditions in SHSY-5Y neurons.
Key Numbers
NTI-164 significantly attenuated microglial inflammatory markers; CBD alone did not; NTI-164 promoted neuron proliferation and survival under excitotoxic conditions.
How They Did This
In vitro study using BV-2 microglial cells and SHSY-5Y neurons to compare anti-inflammatory and neuroprotective effects of a full-spectrum cannabis extract (NTI-164) versus CBD alone.
Why This Research Matters
This study provides direct evidence for the "entourage effect," showing that a whole-plant extract can outperform an isolated cannabinoid. The neuroprotective findings are relevant to conditions like autism spectrum disorder where neuroinflammation plays a role.
The Bigger Picture
The debate between isolated CBD and full-spectrum extracts has major implications for medical cannabis formulation. These in vitro results suggest that minor cannabinoids and terpenes in whole-plant extracts may contribute meaningfully to therapeutic effects.
What This Study Doesn't Tell Us
In vitro study using cell lines, not living brain tissue. Cannot extrapolate directly to human disease. NTI-164 is a specific proprietary extract that may not represent all full-spectrum products.
Questions This Raises
- ?Which specific minor cannabinoids or terpenes in NTI-164 contribute to its superior anti-inflammatory effects?
- ?Would these in vitro advantages translate to clinical benefits in neuroinflammatory conditions?
Trust & Context
- Key Stat:
- Full-spectrum extract reduced inflammation; CBD alone did not
- Evidence Grade:
- In vitro cell study with controlled comparisons, but no in vivo or human data.
- Study Age:
- 2024 publication
- Original Title:
- Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.
- Published In:
- Biomolecules, 14(11) (2024)
- Authors:
- Ross-Munro, Emily, Isikgel, Esra, Fleiss, Bobbi
- Database ID:
- RTHC-05664
Evidence Hierarchy
Frequently Asked Questions
Is full-spectrum cannabis better than CBD alone?
In this cell study, a full-spectrum low-THC extract significantly reduced brain cell inflammation while CBD alone did not. This supports the "entourage effect" concept, though human studies are needed to confirm.
Can cannabis extracts protect brain cells?
This in vitro study found a full-spectrum cannabis extract promoted neuron survival under conditions that mimic brain damage. These are preliminary findings in cell models, not in living brains.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05664APA
Ross-Munro, Emily; Isikgel, Esra; Fleiss, Bobbi. (2024). Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.. Biomolecules, 14(11). https://doi.org/10.3390/biom14111434
MLA
Ross-Munro, Emily, et al. "Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannabis Plant Extract Using In Vitro Models of Inflammation and Excitotoxicity.." Biomolecules, 2024. https://doi.org/10.3390/biom14111434
RethinkTHC
RethinkTHC Research Database. "Evaluation of the Efficacy of a Full-Spectrum Low-THC Cannab..." RTHC-05664. Retrieved from https://rethinkthc.com/research/ross-munro-2024-evaluation-of-the-efficacy
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.